Switching from Semaglutide to Tirzepatide: Key Insights
As the management of type 2 diabetes and obesity continues to evolve, patients and healthcare providers often consider transitioning between therapies to achieve optimal outcomes. A notable transition gaining attention is the switch from semaglutide, a well-established GLP-1 receptor agonist, to tirzepatide, a newer dual GIP/GLP-1 receptor agonist. This blog provides an in-depth look at […]